DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong ...

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

DexCom is down 2.6% since the beginning of the year, and at $76.47 per share, it is trading 15.7% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom’s ...

In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...